Juliet Philips

发表

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

Keith L. Ligon, Sandro Santagata, Mark A. Rubin, 2009, PloS one.

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

P. Jänne, F. Cappuzzo, K. Okuno, 2011, Science Translational Medicine.

Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

Trevor J Pugh, J. Grimsby, N. Lennon, 2013, Nature Genetics.

Genetics of the FANCA gene in familial pancreatic cancer

F. Couch, R. Hruban, G. Petersen, 2004, Journal of Medical Genetics.

High‐resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss

Derek Y. Chiang, D. Zahrieh, R. Shivdasani, 2008, Genes, chromosomes & cancer.

Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer

F. Couch, R. Hruban, S. Kern, 2005, Oncogene.

TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions

Myles A Brown, X. Liu, H. Clevers, 2010, Proceedings of the National Academy of Sciences.

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer

Shuji Ogino, Ellen Freed, J. Meyerhardt, 2009, Clinical Cancer Research.

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

J. Meyerhardt, M. Tzardi, S. Ogino, 2009, British Journal of Cancer.

Relationship of CDX 2 Loss with Molecular Features and Prognosis in Colorectal Cancer

J. Meyerhardt, S. Ogino, C. Fuchs, 2009 .

Evaluation of Temperature Gradient Capillary Electrophoresis for Detection of the Factor V Leiden Mutation

K. Murphy, J. Philips, M. Hafez, 2012, Molecular Diagnosis.

Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

W. Hahn, M. Meyerson, M. Rubin, 2009, PLoS ONE.